Oracle's $40B Financing Plan Highlights Financing Strain as AI Capex Outpaces Cash Generation

What happened

Oracle's aggressive AI datacenter buildout is consuming cash faster than its business generates it, forcing the company to rely on a $40 billion financing plan that includes debt and a $20 billion at-the-market equity program. The new article from 24/7 Wall Street reinforces that the gap between operating cash flow and capital expenditures—evident in Oracle's fiscal 2026 free cash flow of -$23.7 billion—is now a central risk for investors. While demand for Oracle's cloud and AI infrastructure remains strong, with RPO surging to $638 billion, only about 12% of that backlog is expected to convert to revenue within 12 months, prolonging the capital-intensive phase. The financing plan signals that Oracle management expects continued heavy spending before cash generation catches up, which heightens sensitivity to debt costs and dilution. This narrative aligns with the existing DeepValue master report, which already flagged financing strain, negative free cash flow, and the need for faster monetization to justify current valuation.

Implication

The confirmation of Oracle's $40 billion financing plan, including a $20 billion ATM equity issuance, underscores that the company's AI buildout is not yet self-funding and that shareholder dilution risk is real. Near-term performance will hinge on the September 2026 Q1 FY2027 results, where cloud revenue growth must land in the guided 58–64% range and any increase in customer prepayments would signal that the funding burden is being shared. Until the 12-month RPO conversion rate improves materially or customer-funded structures expand, the stock is likely to face continued pressure from debt costs and equity dilution. The buy case remains unattractive at current levels, with a target entry near $135 and a trim threshold around $185, as the market is paying a premium for unproven cash conversion. A failure to meet guidance or any material ATM usage before cash flow inflection would justify a more bearish stance and reduce the fair value toward the $125 bear-case scenario.

Thesis delta

The new article does not introduce fundamentally new information but strengthens the existing thesis that Oracle's financing strain is a dominant near-term risk. It reinforces the view that the stock should be rated WAIT because the market has not yet priced in the full extent of dilution and debt-servicing costs from the $40 billion financing plan. The thesis remains contingent on Q1 FY2027 results and subsequent filings showing improved monetization of the AI backlog.